Abstract

The mechanisms underlying latent-virus-mediated heterologous immunity, and subsequent transplant rejection, especially in the setting of T cell costimulation blockade, remain undetermined. To address this, we have utilized MHV68 to develop a rodent model of latent virus-induced heterologous alloimmunity. MHV68 infection was correlated with multimodal immune deviation, which included increased secretion of CXCL9 and CXCL10, and with the expansion of a CD8dim T cell population. CD8dim T cells exhibited decreased expression of multiple costimulation molecules and increased expression of two adhesion molecules, LFA-1 and VLA-4. In the setting of MHV68 latency, recipients demonstrated accelerated costimulation blockade-resistant rejection of skin allografts compared to non-infected animals (MST 13.5 d in infected animals vs 22 d in non-infected animals, p<.0001). In contrast, the duration of graft acceptance was equivalent between non-infected and infected animals when treated with combined anti-LFA-1/anti-VLA-4 adhesion blockade (MST 24 d for non-infected and 27 d for infected, p = n.s.). The combination of CTLA-4-Ig/anti-CD154-based costimulation blockade+anti-LFA-1/anti-VLA-4-based adhesion blockade led to prolonged graft acceptance in both non-infected and infected cohorts (MST>100 d for both, p<.0001 versus costimulation blockade for either). While in the non-infected cohort, either CTLA-4-Ig or anti-CD154 alone could effectively pair with adhesion blockade to prolong allograft acceptance, in infected animals, the prolonged acceptance of skin grafts could only be recapitulated when anti-LFA-1 and anti-VLA-4 antibodies were combined with anti-CD154 (without CTLA-4-Ig, MST>100 d). Graft acceptance was significantly impaired when CTLA-4-Ig alone (no anti-CD154) was combined with adhesion blockade (MST 41 d). These results suggest that in the setting of MHV68 infection, synergy occurs predominantly between adhesion pathways and CD154-based costimulation, and that combined targeting of both pathways may be required to overcome the increased risk of rejection that occurs in the setting of latent-virus-mediated immune deviation.

Highlights

  • Solid organ transplantation can enhance quality of life, improve clinical outcomes, and even be life-saving for many individuals with organ failure

  • Skin graft survival in the setting of costimulation blockade (CoB) treatment was compared between MHV68infected and non-infected mice to determine whether latent MHV68 augmented the alloimmune response to skin grafts in the stringent BALB/c to B6 system

  • As shown in the figure, latent infection with MHV68 significantly decreased the median survival time (MST) in CoBtreated recipients to 13.5 d (n = 40 from 7 independent experiments, p,.0001 compared to CoB-treated non-infected recipients and p = n.s. compared to non-infected historical controls receiving no immunosuppression) [22,23]

Read more

Summary

Introduction

Solid organ transplantation can enhance quality of life, improve clinical outcomes, and even be life-saving for many individuals with organ failure. While the majority of studies of virus-induced heterologous immunity have employed either acute viral infection models [1,6,7], or transgenic systems which predominantly model singleantigen receptor cross-reactivity [8], the most relevant clinical scenario is one of viral latency, with the most prominent clinical manifestations occurring from two latent viruses: CMV and EBV To accurately recapitulate this clinical scenario, we previously established a model of latent-virus mediated heterologous alloreactivity using the EBV homolog [9,10,11,12] MHV68, and demonstrated that infection with this single latent virus can profoundly influence bone marrow transplant rejection and toleranceinduction [3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call